ACCESS PACK EXPO XPRESS ONLINE TODAY
ACCESS PACK EXPO XPRESS ONLINE TODAY. Content is available on-demand through November 30th.
LEARN MORE

This Drug Shrank Cancer in 80% of Patients

A clinical trial at the University of Michigan showed promise for oral drug zanubrutinib to combat a specific type of lymphoma.

Download

A recent SciTechDaily article discussed a promising new study out of the University of Michigan that could change the way we treat lymphoma. The oral drug zanubrutinib was used to combat a specific type of slow-growing cancer known as marginal zone lymphoma. Results showed that the drug shrank cancer in 80% of the 20 subjects, with a fifth of them going into complete remission.

Zanubrutinib is a novel drug known as a Bruton Tyrosine Kinase inhibitor that blocks a specific enzyme that allows lymphomas to survive and grow. The clinical trial’s  results combined with a secondary study gained the drug FDA approval on a contingent basis for adults with that specific lymphoma that has otherwise been treated unsuccessfully.

Access On-Demand Content Today
Discover innovative solutions for packaging and processing, automation, sustainability, e-commerce and more.
LEARN MORE
Access On-Demand Content Today
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts